People living with diabetes in Pakistan are reportedly struggling to obtain Apidra, a rapid-acting insulin used to control blood sugar levels, amid concerns about its availability in the country.
According to a social media report by Connected Pakistan, patients who have relied on the medication for years are facing uncertainty as supplies become difficult to find.
Apidra (insulin glulisine) is commonly prescribed to help manage the rise in blood glucose associated with meals. For patients who depend on insulin, interruptions in treatment can lead to serious health complications.
The reported shortage has raised concerns about the reliability of medicine supply chains and continued access to essential diabetes treatments.
Patients who are unable to obtain Apidra are advised to contact their prescribing doctor or pharmacist promptly to discuss suitable alternatives.
Medical professionals caution that patients should not discontinue insulin or independently change insulin types or doses, as different formulations may require adjustments to treatment schedules and dosages.
The extent of the reported shortage, its underlying causes and the expected timeline for restoring supplies have not been independently confirmed.
The situation highlights the importance of maintaining reliable access to essential medicines for people managing chronic conditions such as diabetes.